Literature DB >> 24055076

Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Saheem A Zaidi1, Christopher K Arnatt, Hengjun He, Dana E Selley, Philip D Mosier, Glen E Kellogg, Yan Zhang.   

Abstract

Highly selective opioid receptor antagonists are essential pharmacological probes in opioid receptor structural characterization and opioid agonist functional studies. Currently, there is no highly selective, nonpeptidyl and reversible mu opioid receptor antagonist available. Among a series of naltrexamine derivatives that have been designed and synthesized, two compounds, NAP and NAQ, were previously identified as novel leads for this purpose based on their in vitro and in vivo pharmacological profiles. Both compounds displayed high binding affinity and selectivity to the mu opioid receptor. To further study the interaction of these two ligands with the three opioid receptors, the recently released opioid receptor crystal structures were employed in docking studies to further test our original hypothesis that the ligands recognize a unique 'address' domain in the mu opioid receptor involving Trp318 that facilitates their selectivity. These modeling results were supported by site-directed mutagenesis studies on the mu opioid receptor, where the mutants Y210A and W318A confirmed the role of the latter in binding. Such work not only enriched the 'message-address' concept, also facilitated our next generation ligand design and development. Published by Elsevier Ltd.

Entities:  

Keywords:  Automated docking; Crystal structures; GPCR; Mu opioid receptor; Selective antagonists; Site-directed mutagenesis

Mesh:

Substances:

Year:  2013        PMID: 24055076      PMCID: PMC3831368          DOI: 10.1016/j.bmc.2013.08.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  45 in total

Review 1.  Opioid receptor antagonists.

Authors:  H Schmidhammer
Journal:  Prog Med Chem       Date:  1998

Review 2.  Hydrophobicity: is LogP(o/w) more than the sum of its parts?

Authors:  G Eugene Kellogg; D J Abraham
Journal:  Eur J Med Chem       Date:  2000 Jul-Aug       Impact factor: 6.514

Review 3.  New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi
Journal:  Mol Pharmacol       Date:  2012-06-13       Impact factor: 4.436

Review 4.  Naltrexone for the management of alcohol dependence.

Authors:  Raymond F Anton
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

5.  Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Jianyang Chen; Shashidhar K Akubathini; Feng Zhang; David L Stevens; Irina O Beletskaya; Krista L Scoggins; Zhenxian Zhang; Phillip M Gerk; Dana E Selley; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

6.  Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.

Authors:  Ashutosh Tripathi; Micaela Fornabaio; Glen E Kellogg; John T Gupton; David A Gewirtz; W Andrew Yeudall; Nina E Vega; Susan L Mooberry
Journal:  Bioorg Med Chem       Date:  2007-12-04       Impact factor: 3.641

7.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

8.  Structure of the δ-opioid receptor bound to naltrindole.

Authors:  Sébastien Granier; Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; William I Weis; Brian K Kobilka
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

9.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

10.  Structure of the human κ-opioid receptor in complex with JDTic.

Authors:  Huixian Wu; Daniel Wacker; Mauro Mileni; Vsevolod Katritch; Gye Won Han; Eyal Vardy; Wei Liu; Aaron A Thompson; Xi-Ping Huang; F Ivy Carroll; S Wayne Mascarella; Richard B Westkaemper; Philip D Mosier; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

View more
  7 in total

1.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Authors:  Yan Zhang; Dwight A Williams; Saheem A Zaidi; Yunyun Yuan; Amanda Braithwaite; Edward J Bilsky; William L Dewey; Hamid I Akbarali; John M Streicher; Dana E Selley
Journal:  ACS Chem Neurosci       Date:  2016-01-08       Impact factor: 4.418

2.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

3.  Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.

Authors:  Yi Zheng; Xia Li; Piyusha P Pagare; Yunyun Yuan; Xiang-Yang Wang; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2016-11-12       Impact factor: 2.823

4.  Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Authors:  Samuel Obeng; Abdulmajeed Jali; Yi Zheng; Huiqun Wang; Kathryn L Schwienteck; Chongguang Chen; David L Stevens; Hamid I Akbarali; William L Dewey; Mathew L Banks; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

5.  Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.

Authors:  Huiqun Wang; Saheem A Zaidi; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-06       Impact factor: 3.641

6.  Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; David L Stevens; Essie Komla; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-07-23       Impact factor: 4.418

7.  Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.

Authors:  Hongguang Ma; Huiqun Wang; James C Gillespie; Rolando E Mendez; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2021-03-22       Impact factor: 2.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.